» Articles » PMID: 3491425

The Nucleocapsid of Hepatitis B Virus is Both a T-cell-independent and a T-cell-dependent Antigen

Overview
Journal Science
Specialty Science
Date 1986 Dec 12
PMID 3491425
Citations 112
Authors
Affiliations
Soon will be listed here.
Abstract

One characteristic of the immune response during hepatitis B virus (HBV) infection in humans is the vigorous production and subsequent persistence of antibodies of immunoglobulin (Ig) classes M and G to the nucleocapsid antigen (HBcAg). In this study HBcAg was shown to be similarly immunogenic in mice. When injected into athymic (nude) B10.BR and athymic BALB/c mice, HBcAg induced IgM and IgG class antibodies to HBc in spite of the absence of T cells in nude mice. In euthymic mice, HBcAg efficiently stimulated T-cell proliferation in vitro and helper T-cell function in vivo. The dual functions of HBcAg as a T-cell-independent and a T-cell-dependent antigen may explain its enhanced immunogenicity. Denaturation of HBcAg yields a nonparticulate antigen designated HBeAg; when HBeAg was used as the immunogen, antibody production required helper T-cell function. Although HBcAg and HBeAg are serologically distinct, they are structurally related, and in these experiments were highly cross-reactive at the T-cell level. These results suggest that the elevated levels of IgM antibodies to HBc and the enhanced immunogenicity of HBcAg during HBV infection in humans reflect the ability of HBcAg to directly activate B cells to produce antibodies to HBc in the presence or absence of HBcAg- or HBeAg-sensitized T cells.

Citing Articles

Functional B cell deficiency promotes intrahepatic HBV replication and impairs the development of anti-HBV T cell responses.

Zhu D, Du Y, Zhao M, Ablikim D, Huang H, Pan W Hepatol Int. 2024; 19(1):93-105.

PMID: 39630171 DOI: 10.1007/s12072-024-10753-8.


Viral Hepatitis: Host Immune Interaction, Pathogenesis and New Therapeutic Strategies.

Quirino A, Marascio N, Branda F, Ciccozzi A, Romano C, Locci C Pathogens. 2024; 13(9).

PMID: 39338957 PMC: 11435051. DOI: 10.3390/pathogens13090766.


Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen.

Yano Y, Sato I, Imanishi T, Yoshida R, Matsuura T, Ueda Y Diagnostics (Basel). 2024; 14(7).

PMID: 38611641 PMC: 11011781. DOI: 10.3390/diagnostics14070728.


Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component.

Su J, Harati Taji Z, Kosinska A, Ates Oz E, Xie Z, Bielytskyi P JHEP Rep. 2024; 6(4):100997.

PMID: 38425450 PMC: 10904195. DOI: 10.1016/j.jhepr.2023.100997.


Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics.

Hu J, Huang A Virol Sin. 2023; 39(1):9-23.

PMID: 38110037 PMC: 10877440. DOI: 10.1016/j.virs.2023.12.005.